SON DAKİKA
--:--:--

Japan’s Rapidus Initiates Trial Production on Groundbreaking 2nm Process

0 Yorum Yapıldı
Bağlantı kopyalandı!
Japan’s Rapidus Initiates Trial Production on Groundbreaking 2nm Process

Rapidus Pioneers Japan’s Semiconductor Future with 2nm Trial Production

Rapidus Pioneers Japan's Semiconductor Future with 2nm Trial Production

The Japanese state-sponsored chip manufacturer, Rapidus, is gearing up to initiate trial production of its cutting-edge 2nm manufacturing process later this month. As reported by Bloomberg, the company is targeting the completion of its initial test wafers by July, followed by the release of process design kits (PDKs) to facilitate prototyping for initial customers.

Japan’s Semiconductor Advancement Underway

In the latter part of the previous year, Rapidus began outfitting its Innovative Integration for Manufacturing (IIM) facility in Chitose, Hokkaido, with the latest in semiconductor manufacturing technology. This setup includes advanced EUV and DUV lithography systems from ASML. The company is believed to have reached the ‘first light’ stage with these sophisticated tools, signifying its capability to produce circuits using the 2nm process based on Gate-All-Around (GAA) transistor architecture.

Rapidus offers a strategic advantage over industry behemoths like TSMC, Samsung Foundry, and Intel Foundry by aiming to integrate fully automated advanced packaging processes within the same facility. This integration could substantially reduce production times for designs requiring advanced packaging. However, initially, Rapidus will concentrate on wafer production without providing test packaging services.

To enhance its manufacturing processes, Rapidus is establishing a new research and development center named Rapidus Chiplet Solutions (RCS) at Seiko Epson’s Chitose site. Preparations for RCS began in October 2024, with production equipment installation slated for this month. The facility will focus on developing scalable manufacturing techniques, addressing crucial stages such as redistribution layer (RDL) interposer structures, three-dimensional packaging methods, complex assembly design kits (ADK), and QAD (rugged chip) testing processes.

The CEO of Rapidus, Dr. Atsuyoshi Koike, emphasized that the production facilities are advancing as scheduled, with the pilot production line expected to be operational by the end of this fiscal year. The company also aspires to commence mass production of the 2nm process by 2027, aligning its timeline with that of its global competitors.

Reklam 7Reklam 394ffReklam 409Reklam 678

Yorum Yap

Benzer Haberler
Helsinki Airport Reopens After Three-Hour Closure Over Suspected Drone
Helsinki Airport Reopens After Three-Hour Closure Over Suspected Drone
Marco Rubio Addresses Social Media Debate Over Grey Nike Tracksuit During China Visit
Marco Rubio Addresses Social Media Debate Over Grey Nike Tracksuit During China Visit
Trump Concludes Two-Day Visit to China After Talks With Xi Jinping
Trump Concludes Two-Day Visit to China After Talks With Xi Jinping
Global Sumud Fleet Resumes Journey to Gaza After Previous Israeli Intervention
Global Sumud Fleet Resumes Journey to Gaza After Previous Israeli Intervention
Ukraine Prioritises AI-Powered Drone Swarms in Defence Strategy
Ukraine Prioritises AI-Powered Drone Swarms in Defence Strategy
Iran Says It Is Trying to Preserve Ceasefire to Keep Diplomacy Open
Iran Says It Is Trying to Preserve Ceasefire to Keep Diplomacy Open
En Güncel ve Doğru Haberler!
Sigorta Haber

Sigortahaber.com, sigorta sektöründeki en güncel haberleri, analizleri ve gelişmeleri tarafsız bir bakış açısıyla sunan bağımsız bir haber platformudur. Sigorta profesyonellerine, acentelere ve sektöre ilgi duyan herkese doğru, hızlı ve güvenilir bilgi sağlamayı amaçlıyoruz. Sigortacılıktaki yenilikleri, mevzuat değişikliklerini ve sektör trendlerini yakından takip ederek, okuyucularımıza kapsamlı bir bilgi kaynağı sunuyoruz.

2025 Sigorta Haber © Tüm hakları saklıdır. Sitemizde yer alan Ekonomi ve Finans kategorilerindeki içerikler yalnızca bilgilendirme amaçlıdır; herhangi bir yatırım tavsiyesi niteliği taşımaz. Sağlık ve Bilgi kategorisinde bulunan içerikler genel olarak yapay zekâ tarafından üretilmiş olup yalnızca bilgilendirme amacı taşır. Herhangi bir sağlık sorunu yaşıyorsanız, burada yer alan bilgileri esas almak yerine en kısa sürede uzman bir doktora başvurmanız önerilir.